USE OF CANNABIDIOL PRODUCTS BY PET OWNERS IN SLOVENIA: A SURVEY-BASED STUDY
DOI:
https://doi.org/10.26873/SVR-1294-2022Abstract
The aim of the present study was to obtain information about the experiences of Slovenian pet owners on the use of cannabidiol (CBD) products in their pets. An open online survey targeted Slovenian owners of cats and dogs who have used CBD to treat their pets. Questions pertained to demographic data, animal data, health status of the animals, CBD formulations and experiences with use. Descriptive statistics and frequency distributions were performed using the survey software. A total of 41 respondents participated in the survey, most of whom were female (87.8 %) and between 31 and 50 years old (56.1 %). Most respondents (90.2 %) were dog owners. Cannabidiol (CBD)-based products were mainly used to treat orthopedic and oncologic conditions, as adjunctive therapy to other medications. Oil formulations were used by most dog (85.2 %) and all cat owners. Participants predominantly re-ported positive effects, such as improved well-being, increased activity, and reduced pain. The results suggest that Slovenian pet owners who used CBD-based products as a treatment for their pets were overall satisfied with the effects of these products. However, there were still reports of some adverse effects, such as drowsiness, increased appetite, and thirst. Further research is essential to improve practices related to cannabis-based medicines for pets, especially CBD, and to put an end to the trial- and error- based therapeutic approach of pet owners and veterinarians. Long-term, large-scale research studies are needed to clarify the role of CBD as a treatment option for osteoarthritis, chronic pain, cancer, behavioral problems, and other chronic inflammatory conditions in dogs and cats.
Key words: cannabis; cannabidiol; cats; dogs; survey
UPORABA KANABIDIOLA PRI LASTNIKIH HIŠNIH LJUBLJENČKOV V SLOVENIJI – ANKETNA ŠTUDIJA
Izvleček: Namen raziskave je bil pridobiti informacije o izkušnjah slovenskih lastnikov psov in mačk z uporabo izdelkov s kanabidiolom (CBD) pri svojih živalih. Raziskavo smo izvedli na podlagi anonimne spletne ankete, ki je bila namenjena slovenskim lastnikom psov in mačk, ki so uporabljali CBD za zdravljenje svojih živali. Vprašanja so se nanašala na demografske podatke, podatke o živalih, njihovem zdravstvenem stanju, vrste pripravkov s CBD-jem in izkušnjah z uporabo. Za opisno statistiko in frekvenčno porazdelitev smo uporabili programsko opremo za anketiranje. V raziskavi je sodelovalo 41 anketirancev, med katerimi je bilo največ žensk (87,8%) in starih med 31 in 50 let (56,1%). Večina anketirancev (90,2%) je bila lastnikov psov. Izdelki na osnovi CBD-ja so se večinoma uporabljali za zdravljenje ortopedskih in onkoloških obolenj kot dopolnilno zdravljenje. Največ lastnikov psov (85,2%) in vsi lastniki mačk so uporabljali oljne pripravke. Sodelujoči so večinoma poročali o pozitivnih učinkih, kot so boljše počutje, povečanje aktivnosti in zmanjšanje bolečine. Rezultati kažejo, da so slovenski lastniki psov in mačk, ki uporabljajo izdelke na osnovi CBD-ja za zdravljenje svojih živali, na splošno zadovoljni z učinki teh proizvodov. Poročali so tudi o nekaterih neželenih učinkih, kot so zaspanost, povečan apetit in žeja. Nadaljnje raziskave so bistvenega pomena za izboljšanje praks uporabe zdravil na osnovi konoplje za pse in mačke, zlasti CBD, in za odpravo terapevtskega pristopa lastnikov in veterinarjev, ki temelji na poskusih in napakah. Dolgoročne in obširne raziskave so potrebne za jasno opredelitev vloge CBD-ja pri zdravljenju kroničnih bolečin, raka, vedenjskih težav, osteoartritisa in drugih kroničnih vnetnih stanj pri psih in mačkah.
Ključne besede: konoplja; kanabidiol; mačke; psi; anketa
References
● 1. Brutlag A, Hommerding H. Toxicology of mari-juana, synthetic cannabinoids, and cannabidiol in dogs and cats. Vet Clin North Am Small Anim Pract 2018; 48: 1087–102. doi: 10.1016/j.cvsm.2018.07.008
● 2. Zuardi AW. History of cannabis as a medicine: a review. Rev Bras Psiquiatr 2006; 28: 153–7. doi: 10.1590/s1516-44462006000200015
● 3. Mead A. Legal and regulatory issues governing cannabis and cannabis-derived products in the United States. Front Plant Sci 2019; 10. e697. doi: 10.3389/fpls.2019.00697
● 4. European Monitoring Centre for drugs and drug addiction. Cannabis legislation in Europe: an overview. Luxembourg : Publications Office of the European Union, 2018: 1–32. https://op.europa.eu/en/publication-detail/-/publication/a492916b-7822-11e8-ac6a-01aa75ed71a1 (9. 5. 2022).
● 5. Zakon o zdravilih. Ur List RS 2014; 14(17): 1894–944, 2019; 19(66). http://www.pisrs.si/Pis.web/pregledPredpisa?id=ZAKO6295 (2. 5. 2022)
● 6. Zakon o lekarniški dejavnosti. Ur List RS 2016; 16 (85), 2017; 17(77), 2019; 19(73), 2021; 21(186). http://www.pisrs.si/Pis.web/pregledPredpisa?id=ZAKO7375 (02. 05. 2022).
● 7. European Commission. Novel food catalogue. https://ec.europa.eu/food/safety/novel_food/catalogue/search/public/index.cfm (02. 05. 2022)
● 8. Bartner LR, McGrath S, Rao S, Hyatt LK, Wit-tenburg LA. Pharmacokinetics of cannabidiol admin-istered by 3 delivery methods at 2 different dosages to healthy dogs. Can J Vet Res 2018; 82: 178–83.
● 9. Zuardi AW. Cannabidiol: from an inactive can-nabinoid to a drug with wide spectrum of action. Braz J Psychiatry 2008; 30: 271–80. doi: 10.1590/s1516-44462008000300015
● 10. Silver RJ. The endocannabinoid system of ani-mals. Animals (Basel) 2019; 9: 1–15. doi: 10.3390/ani9090686
● 11. Pertwee RG. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J 2005; 7: 625–54. doi: 10.1208/aapsj070364
● 12. Fitzgerald KT, Bronstein AC, Newquist KL. Marijuana poisoning. Top Companion Anim Med 2013; 28: 8–12. doi: 10.1053/j.tcam.2013.03.004
● 13. Meola SD, Tearney CC, Haas SA, Hackett TB, Mazzaferro EM. Evaluation of trends in marijuana toxicosis in dogs living in a state with legalized medical marijuana: 125 dogs (2005–2010). J Vet Emerg Crit Care 2012; 22: 690–6. doi: 10.1111/j.1476-4431.2012.00818.x
● 14. Godbold JC, Hawkins BJ, Woodward MG. Acute oral marijuana poisoning in the dog. J Am Vet Med Assoc 1979; 175: 1101–2.
● 15. Janeczek A, Zawadzki M, Szpot P, et al. Mariju-ana intoxication in a cat. Acta Vet Scand 2018; 60: 44. doi: 10.1186/s13028-018-0398-0.
● 16. Amanollahi R, Soltaninejad H, Ghasemkhani N. Cannabis poisoning in a cat. Onl J Vet Res 2020; 24: 434–7.
● 17. Gamble L-J, Boesch JM, Frye CW, et al. Phar-macokinetics, safety, and clinical efficacy of cannabidi-ol treatment in osteoarthritic dogs. Front Vet Sci 2018; 5. e165. doi: 10.3389/fvets.2018.00165
● 18. Brioschi FA, Di Cesare F, Gioeni D, et al. Oral transmucosal cannabidiol oil formulation as part of a multimodal analgesic regimen: effects on pain relief and quality of life improvement in dogs affected by spontaneous osteoarthritis. Animals 2020; 10: e1505. doi: 10.3390/ani10091505
● 19. Kogan L, Hellyer P, Downing R. The use of cannabidiol-rich hemp oil extract to treat canine oste-oarthritis-related pain: a pilot study. Am Holist Vet Med Assoc J 2020; 58: 35–45.
● 20. Verrico CD, Wesson S, Konduri V, et al. A randomized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteo-arthritis pain. Pain 2020; 161: 2191–202. doi: 10.1097/j.pain.0000000000001896.
● 21. Mejia S, Duerr FM, Griffenhagen G, McGrath S. Evaluation of the effect of cannabidiol on naturally occurring osteoarthritis-associated pain: a pilot study in dogs. J Am Anim Hosp Assoc 2021; 57: 81–90 doi: 10.5326/JAAHA-MS-7119
● 22. McGrath S, Bartner LR, Rao S, Packer RA, Gustafson DL. Randomized blinded controlled clini-cal trial to assess the effect of oral cannabidiol admin-istration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy. J Am Vet Med Assoc 2019; 254: 1301–8. doi: 10.2460/javma.254.11.1301
● 23. Mogi C, Fukuyama T. Cannabidiol as a poten-tial anti-epileptic dietary supplement in dogs with sus-pected epilepsy: three case reports. Pet Behav Sci 2019; 7: 11–6. doi: 10.21071/pbs.v0i7.11800
● 24. Mogi C, Yoshida M, Kawano K, Fukuyama T, Arai T. Effects of cannabidiol without delta-9-tetrahydrocannabinol on canine atopic dermatitis: a retrospective assessment of 8 cases. Can Vet J 2022; 63: 423–6.
● 25. Morris EM, Kitts-Morgan SE, Spangler DM, McLeod KR, Costa JHC, Harmon DL. The impact of feeding cannabidiol (CBD) containing treats on canine response to a noise-induced fear response test. Front Vet Sci 2020; 7: e690. doi: 10.3389/fvets.2020.569565
● 26. Deabold KA, Schwark WS, Wolf L, Wakshlag JJ. Single-dose pharmacokinetics and preliminary safe-ty assessment with use of CBD-rich hemp nutraceuti-cal in healthy dogs and cats. Animals 2019; 9: e832. doi: 10.3390/ani9100832
● 27. Łebkowska-Wieruszewska B, Stefanelli F, Chericoni S, et al. Pharmacokinetics of Bedrocan® a cannabis oil extract, in fasting and fed dogs: an ex-plorative study. Res Vet Sci 2019; 123: 26–8. doi: 10.1016/j.rvsc.2018.12.003
● 28. Mcgrath S, Bartner LR, Rao S, Kogan LR, Hellyer PW. A report of adverse effects associated with the administration of cannabidiol in healthy dogs. Am Holist Vet Med Assoc J 2018; 52: 34–8.
● 29. Vaughn D, Kulpa J, Paulionis L. Preliminary in-vestigation of the safety of escalating cannabinoid doses in healthy dogs. Front Vet Sci 2020; 7: e51. doi 10.3389/fvets.2020.00051
● 30. Wakshlag JJ, Schwark WS, Deabold KA, et al. Pharmacokinetics of cannabidiol, cannabidiolic acid, Δ9-tetrahydrocannabinol, tetrahydrocannabinolic acid and related metabolites in canine serum after dosing with three oral forms of hemp extract. Front Vet Sci 2020; 7: e505. doi: 10.3389/fvets.2020.00505
● 31. Kulpa JE, Paulionis LJ, Eglit GM, Vaughn DM. Safety and tolerability of escalating cannabinoid doses in healthy cats. J Feline Med Surg 2021; 23: 1162–75. doi: 10.1177/1098612X211004215
● 32. Kogan LR, Hellyer PW, Robinson NG. Con-sumers’ perceptions of hemp products for animals. Am Holist Vet Med Assoc J 2016; 42: 40–8.
● 33. Kogan LR, Hellyer PW, Schoenfeld-Tacher R. Dog owners’ use and perceptions of cannabis prod-ucts. Am Holist Vet Med Assoc J 2018; 51: 26–33.
● 34. Kogan LR, Hellyer PW, Silcox S, Schoenfeld-Tacher R. Canadian dog owners’ use and perceptions of cannabis products. Can Vet J 2019; 60: 749–55.
● 35. Inkol JM, Hocker SE, Mutsaers AJ. Combina-tion therapy with cannabidiol and chemotherapeutics in canine urothelial carcinoma cells. PLoS One 2021; 16: e0255591. doi: 10.1371/journal.pone.0255591.
● 36. Henry JG, Shoemaker G, Prieto JM, Hannon MB, Wakshlag JJ. The effect of cannabidiol on canine neoplastic cell proliferation and mitogen-activated protein kinase activation during autophagy and apop-tosis. Vet Comp Oncol 2021; 19: 253–65. doi: 10.1111/vco.12669
● 37. Tomsič K, Rakinić, K, Seliškar A. Slovenian pet owners’ experience, attitudes, and predictors regarding cannabinoid use in dogs and cats. Front Vet Sci 2022; 8: e796673. doi: 10.3389/fvets.2021.796673.
● 38. Kogan L, Schoenfeld-Tacher R, Hellyer P, Rishniw M. US veterinarians’ knowledge, experience, and perception regarding the use of cannabidiol for canine medical conditions. Front Vet Sci 2019; 5: e338. doi: 10.3389/fvets.2018.00338
● 39. Vogt NA, Sargeant JM, Stevens CPG, Dunn JN. A survey of veterinary student attitudes concern-ing whether marijuana could have therapeutic value for animals. PLoS One 2019; 14: e0219430. doi: 10.1371/journal.pone.0219430
● 40. Eysenbach G. Improving the quality of Web surveys: the checklist for reporting results of internet e-surveys (CHERRIES). J Med Internet Res 2004; 6: e34. doi: 10.2196/jmir.6.3. e34
● 41. Cozzi B, Ballarin C, Mantovani R, Rota A. Ag-ing and veterinary care of cats, dogs, and horses through the records of three university veterinary hospitals. Front Vet Sci 2017; 4: e14. doi: 10.3389/fvets.2017.00014
● 42. Campora L, Miragliotta V, Ricci E, Cristino L, Di Marzo V, Albanese F, et al. Cannabinoid receptor type 1 and 2 expression in the skin of healthy dogs and dogs with atopic dermatitis. Am J Vet Res 2012; 73: 988–95.
● 43. Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling accuracy of cannabidiol extracts sold online. J Am Med Assoc 2017; 318: 1708–9.
● 44. Vandrey R, Raber JC, Raber ME, Douglass B, Miller C, Bonn-Miller MO. Cannabinoid dose and label accuracy in edible medical cannabis products. J Am Med Assoc 2015; 313: 2491–3.
● 45. Amissah RQ, Vogt NA, Chen C, Urban K, Khokhar J. Prevalence and characteristics of cannabis-induced toxicoses in pets: results from a survey of veterinarians in North America. PLoS One 2022; 17: e0261909. doi: 10.1371/journal.pone.0261909
● 46. Hartsel JA, Boyar K, Pham A, Silver RJ, Ma-kriyannis A. Cannabis in veterinary medicine: canna-binoid therapies for animals. In: Gupta R, Srivastava A, Lall R, eds. Nutraceuticals in veterinary medicine. Cham : Springer, 2019: 121–55. https://doi.org/10.1007/978-3-030-04624-8_10
● 47. Hazzah T, André CM, Richter G, McGrath S. Cannabis in veterinary medicine: a critical review. Am Holist Vet Med Assoc J 2020; 61: 17–41.
● 48. Wallace JE, Kogan LR, Carr ECJ, Hellyer PW. Motivations and expectations for using cannabis products to treat pain in humans and dogs: a mixed methods study. J Cannabis Res 2020; 2: e36. doi: 10.1186/s42238-020-00045-x
● 49. Kruger DJ, Kruger JS. Medical cannabis users’ comparisons between medical cannabis and main-stream medicine. J Psychoactive Drugs 2019; 51: 31–6.
● 50. Porter BE, Jacobson C. Report of a parent sur-vey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav 2013; 29: 574–7.
● 51. Wang GS. Pediatric concerns due to expanded cannabis use: unintended consequences of legalization. J Med Toxicol 2017; 13: 99–105.
● 52. Conzemius MG, Evans RB. Caregiver placebo effect for dogs with lameness from osteoarthritis. J Am Vet Med Assoc 2012; 241: 1314–9.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 SLOVENIAN VETERINARY RESEARCH
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
